2018 American Transplant Congress
The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients
TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.
Purpose: Post-transplant (Tx) bacterial and viral infections are known to affect graft and patient survival. Accumulating evidence supports the protective effect of everolimus (EVR) against…2018 American Transplant Congress
Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients is Associated with Prolonged Cold Ischemic Time of Seropositive Donor Organs
Introduction: Human Cytomegalovirus (CMV) infection is still a major risk factor for immunocompromised patients, e.g. kidney recipients. Based on the CMV serostatus of donor (D)…2018 American Transplant Congress
Clinical Utility of CMV-Specific CD8+ T-Cell Immune Competence Score in Lung and Heart-Lung Transplant Recipients at Risk of Cytomegalovirus Infection
Introduction: Cytomegalovirus (CMV) is a common infection that causes significant morbidity among lung and heart-lung (LHL) transplant recipients. We determined the clinical utility of global…2018 American Transplant Congress
Cytomegalovirus (CMV) Infection in Small Intestinal and Multivisceral Transplant Recipients: The Role of Donor Selection on CMV Incidence and Outcomes
Medstar Georgetown University Hospital, Washington DC.
Introduction: CMV infection remains an important cause of morbidity, allograft enteritis, and allograft loss in small intestinal (SIT) and multivisceral transplant (MVT) recipients. As the…2018 American Transplant Congress
Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients
Henry Ford Hospital, Detroit, MI.
Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…2018 American Transplant Congress
Identifying Specificity Groups in the CMV IE-1 T Cell Receptor Repertoire
Cytomegalovirus (CMV) continues to be a major problem for organ transplant recipients. T cells specific to the CMV antigens immediate-early (IE-1) and pp65 CMV govern…2018 American Transplant Congress
Th17 and NK Responses Are Differentially Induced in Renal Allografts According to Recipient Murine Cytomegalovirus Dose and Strain
Purpose: To study the impact of cytomegalovirus (CMV) recipient positive (R+) serostatus upon renal allograft injury, murine CMV (MCMV) D+/R+ kidney transplants using recipients infected…2018 American Transplant Congress
Recovery of Wild-Type Genotype after Documented Ganciclovir-Resistance in Transplant Recipients with Recurrent CMV Viremia
Purpose: Ganciclovir-resistant cytomegalovirus (GR-CMV) is serious complication after transplantation. Recurrence after primary GR-CMV infection is common, with literature defined rates of approximately 20-30%. It is…2018 American Transplant Congress
Evaluation of the Use of Oral Valganciclovir for the Treatment of Cytomegalovirus Infections in Pediatric Intestinal Transplant Recipients: A Single Center Review
Purpose: To evaluate the safety and efficacy of oral valganciclovir in treating cytomegalovirus (CMV) infections in pediatric intestinal transplant recipients (pITR).Methods: This retrospective review included…2018 American Transplant Congress
Alveolar Macrophages Derived from MCMV Latently Infected Donors Drives the Viral Reactivation and Dissemination Following the Orthotopic Left Lung Transplantation in Mice
Background: The incidence of cytomegalovirus (CMV) disease is higher in lung transplants, than in other SOT recipients, especially in high-risk D+/R- recipients. Using a murine…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 33
- Next Page »